While anti-angiogenic therapies were developed because pathological angiogenesis relied on VEGF/VEGFR signaling, bulk and single-cell transcriptomic studies reveal a complex heterogeneity of the tumor vasculature, which should guide the design of rational therapeutic regimens [26]. The gene discussed is VEGFA; the disease is neoplasm.